Abstract: A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.

Abstract: An object of the present invention is to establish means for providing a component vaccine which can elicit immunity to a non-structural protein. The present inventors have found that the object can be attained by providing a component vaccine containing an associated product containing a trimer and/or a hexamer of a molecular needle to which a non-structural protein of a pathogenic virus is attached.

Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.

Abstract: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising, as an active ingredient, a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT). Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof. [In the formulas, each of formula (III) and formula (IV) represents an ?-anomer or a ?-anomer; each of R4, R3, and R4 is —OH or -OAc; R2 is a halogen atom, —OH, or -OAc; and R5 is —CH3, —C?CH, —C?CCH3, or —CH2C?CH.

Abstract: A laboratory test kit includes a development part 12 for developing thereon a test sample containing a virus, reagent portion 13 and a recognition portion 17. On the recognition portion 17, first and second specific antibodies both derived from a mouse are to be immobilized for specifically recognizing first and second antigen-determining sites respectively both possessed by the virus. The reagent portion 13 includes first and second labeled antibodies both derived from a mouse, which specifically recognize the first and second antigen-determining sites respectively both possessed by the virus and are labeled with a labeling substance. In each of the first and second labeled antibodies, at least one of an antigen site which is recognized by the HAMA or a sugar chain binding site recognized by an antibody which recognizes a sugar chain is defected or modified.

Abstract: An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.